Form 4: Caris Life Sciences Director Acquires Equity Compensation

Caris Life Sciences Director T Danny Phillips acquired 3,739 shares of common stock at $20.06, increasing his beneficial ownership to 119,868 shares.

Summary

• T Danny Phillips, a Director of Caris Life Sciences, Inc. (CAI), acquired 3,739 shares of common stock.
• The transaction occurred on February 26, 2026, with shares priced at $20.06 each.
• These shares were issued in lieu of cash compensation for 2025 board retainer fees.
• The number of shares was determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
• Following this acquisition, T Danny Phillips beneficially owns a total of 119,868 shares of Caris Life Sciences common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their equity stake, even through compensation, aligns their interests further with shareholders. It does not, however, indicate a direct investment decision based on new information.

Positives

• A Director's acquisition of shares, even as compensation, can signal continued alignment of interests with shareholders.
• The transaction increases the Director's direct stake in the company, demonstrating commitment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of shares by a director, are routinely monitored by investors as they can provide insights into management's confidence in the company's prospects. While this specific transaction is for compensation rather than an open-market purchase, it still represents an increase in insider ownership.

Related Party Transactions

• The acquisition of shares by Director T Danny Phillips in lieu of cash compensation for board retainer fees can be considered a related party transaction, as it involves a transaction between the company and a member of its management.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director received shares as compensation. While it slightly increases insider ownership, it does not provide sufficient new information about the company's operational performance, financial health, or strategic direction to warrant a change in investment recommendation. A seasoned investor would consider this a minor data point within a broader analysis.

Keywords

Caris Life Sciences, CAI, Form 4, Insider Transaction, Director Stock Acquisition, Equity Compensation, Beneficial Ownership